$ALLK News

Last published 1y ago

1y agoALLKAllakos Inc. Enters into Agreement to Be Acquired by Concentra Biosciences, LLC for $0.33 in Cash per ShareGlobeNewswireSAN CARLOS, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Allakos Inc. ("Allakos") (NASDAQ:ALLK), a biotechnology company that has been developing antibodies for the treatment of allergic, inflammatory and proliferative
1y agoALLKAllakos Provides Business Update and Reports Fourth Quarter 2024 Financial ResultsGlobeNewswireSAN CARLOS, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Allakos Inc. (the "Company") (NASDAQ:ALLK), a biotechnology company that has been developing antibodies for the treatment of allergic, inflammatory and
1y agoALLKLycia Therapeutics Announces the Appointment of Chin Lee, MD, MPH, as Chief Medical Officer and Reveals Immunology PipelineGlobeNewswireSOUTH SAN FRANCISCO, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Lycia Therapeutics, Inc., a biotechnology company developing lysosomal targeting chimera (LYTAC)-based protein degradation therapies to eliminate disease
1y agoALLKKuehn Law Encourages Investors of Allakos Inc. to Contact Law FirmGlobeNewswireNEW YORK, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Allakos Inc. (NASDAQ:ALLK) breached their fiduciary duties to
1y agoALLKAllakos Announces Topline Results from its Phase 1 Trial of AK006 in Patients with Chronic Spontaneous Urticaria and Announces RestructuringGlobeNewswire– AK006 did not demonstrate therapeutic activity in CSU –– Allakos will discontinue further development of AK006, reduce workforce by 75% and explore strategic alternatives –– Management to host conference call and
1y agoALLKKuehn Law Encourages Investors of Allakos Inc. to Contact Law FirmPR NewswireKuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Allakos Inc. (NASDAQ: ALLK) breached...
2y agoALLKAllakos Provides Business Update and Reports Third Quarter 2024 Financial ResultsGlobeNewswireSAN CARLOS, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the "Company") (NASDAQ:ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases,
2y agoALLKAllakos Announces Phase 1 Trial Results of Subcutaneous AK006 in Healthy VolunteersGlobeNewswire– Subcutaneously administered AK006 showed approximately 77% bioavailability and prolonged receptor occupancy on mast cells –– Subcutaneous AK006 was well-tolerated with a favorable safety profile –– Top-line Phase 1
2y agoALLKAllakos Provides Business Update and Reports Second Quarter 2024 Financial ResultsGlobeNewswireSAN CARLOS, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the "Company") (NASDAQ:ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases,
2y agoALLKAllakos Announces Positive Results from its Ongoing Phase 1 Trial of AK006 in Healthy Volunteers, with AK006 Demonstrating High Receptor Occupancy on Mast Cells and a Favorable Safety ProfileGlobeNewswire– AK006 achieved serum concentrations consistent with levels demonstrating inhibitory activity in preclinical experiments –– Skin biopsies from subjects treated with AK006 show high receptor occupancy –– AK006 was
2y agoALLKAllakos Announces First Patient Dosed in Phase 1 Trial of AK006 in Chronic Spontaneous UrticariaGlobeNewswire– Top-line Phase 1 CSU results expected at year end 2024 – SAN CARLOS, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ:ALLK), a biotechnology company developing AK006 for the treatment of mast
2y agoALLKAllakos Provides Business Update and Reports First Quarter 2024 Financial ResultsGlobeNewswireSAN CARLOS, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the "Company") (NASDAQ:ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases,
2y agoALLKAllakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsGlobeNewswireSAN CARLOS, Calif., March 14, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the "Company") (NASDAQ:ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases,
2y agoALLKAllakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024GlobeNewswire– Atopic dermatitis and prurigo nodularis skin lesions show evidence of MRGPRX2 mast cell activation and activated macrophages – – AK006 inhibited mast cell activation and reduced mast cell numbers in an
2y agoALLKAllakos Announces Publication Highlighting AK006 Mast Cell InhibitionGlobeNewswire– Data provide insights on the signaling pathways involved with AK006 mast cell inhibition –– AK006 has a distinct mechanism of action that leads to broad inhibitory effects on mast cells – SAN CARLOS, Calif., Feb.
2y agoALLKAllakos Announces a Restructuring to Focus on Development of AK006GlobeNewswireExisting cash to fund planned ongoing operations into mid-2026AK006 is being tested in a comprehensive Phase 1 clinical program, including: ongoing single and multiple ascending dose trial in healthy volunteersa
2y agoALLKAllakos Announces Phase 2 Lirentelimab Trials in Atopic Dermatitis and Chronic Spontaneous Urticaria Did Not Meet Their Primary EndpointsGlobeNewswire– Allakos plans not to pursue further development of lirentelimab; will focus on AK006 clinical development and additional preclinical programs – – Management to host conference call and webcast today at 8:00 am
2y agoALLKAllakos Provides Business Update and Reports Third Quarter 2023 Financial ResultsGlobeNewswireSAN CARLOS, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (the "Company") (NASDAQ:ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases,
3y agoALLKAllakos Appoints Neil Graham to its Board of DirectorsGlobeNewswireSAN CARLOS, Calif., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ:ALLK), a clinical-stage biotechnology company developing therapeutics which target immunomodulatory receptors present on immune effector cells
3y agoALLKAllakos Provides Business Update and Reports Second Quarter 2023 Financial ResultsGlobeNewswireSAN CARLOS, Calif., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (the "Company") (NASDAQ:ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases,
3y agoALLKAllakos Appoints Rand Sutherland and Dolca Thomas to its Board of DirectorsGlobeNewswireSAN CARLOS, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ:ALLK), a clinical-stage biotechnology company developing therapeutics which target immunomodulatory receptors present on immune effector cells
3y agoALLKAllakos Presents Preclinical Data at EAACI Hybrid Congress 2023 Highlighting Lirentelimab and AK006 Mechanisms of Mast Cell InhibitionGlobeNewswire– AK006 inhibits IgE mediated mast cell activation and shows similar IgE inhibitory activity as remibrutinib –– AK006 also inhibits non-IgE mast cell activation pathways, including KIT-mediated activation– SAN CARLOS,
3y agoALLKAllakos Announces Upcoming Presentation on Lirentelimab and AK006 Mast Cell Inhibition at the European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2023GlobeNewswireSAN CARLOS, Calif., June 05, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ:ALLK), a clinical-stage biotechnology company developing therapeutics which target immunomodulatory receptors present on immune effector cells
3y agoALLKAllakos Provides Business Update and Reports First Quarter 2023 Financial ResultsGlobeNewswireSAN CARLOS, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (the "Company") (NASDAQ:ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases,
3y agoALLKAllakos Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial ResultsGlobeNewswireSAN CARLOS, Calif., March 06, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (the "Company") (NASDAQ:ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases,
3y agoALLKAllakos Announces Publication of AK006 Mechanism of Action Manuscript in Communications BiologyGlobeNewswire– AK006 is an agonistic antibody that targets the mast cell inhibitory receptor Siglec-6 –– AK006 shows deep mast cell inhibition in pre-clinical studies and was engineered to have antibody-dependent cellular
4y agoALLKAllakos Presents Preclinical Data on AK007, a Siglec-10 Antagonist Antibody, at the Society for Immunotherapy of Cancer's 37th Annual MeetingGlobeNewswire– Siglec-10 is a myeloid checkpoint receptor selectively expressed on tumor associated macrophages and dendritic cells –– AK007 potently blocks all known ligand interaction with Siglec-10, including the "don't eat me"
4y agoALLKAllakos Provides Business Update and Reports Third Quarter 2022 Financial ResultsGlobeNewswireSAN CARLOS, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the "Company") (NASDAQ:ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inflammatory
4y agoALLKAllakos Announces Pricing of $150 Million Underwritten Offering of Common StockGlobeNewswireSAN CARLOS, Calif., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ:ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inflammatory diseases, today announced the pricing of an underwritten
4y agoALLKAllakos Announces Initiation of Phase 2b Clinical Trial of Subcutaneous Lirentelimab in Chronic Spontaneous Urticaria (CSU)GlobeNewswireSAN CARLOS, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ:ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inflammatory diseases, today announced it has initiated a Phase 2b cl
4y agoALLKAllakos Announces Topline Phase 3 Data from the EoDyssey Study in Patients with Eosinophilic DuodenitisGlobeNewswire– Lirentelimab met histologic co-primary endpoint but missed symptomatic co-primary endpoint – SAN CARLOS, Calif., Sept. 09, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the "Company") (NASDAQ:ALLK), a biotechnology company developing lirentelimab (AK
4y agoALLKA Study to Assess Subcutaneous Lirentelimab (AK002) in Chronic Spontaneous Urticaria - NCT05528861ClinicalTrials.govAbsolute change in weekly Urticaria Activity Score (UAS7) from baseline to Week 12, Absolute change in Hives Severity Score (HSS7) from baseline to Week 12, Absolute change in Itch Severity Scale (ISS7) from baseline to Week 12, Proportion of subjects achieving UAS7=0
4y agoALLKAllakos Provides Business Update and Reports Second Quarter 2022 Financial ResultsGlobeNewswireSAN CARLOS, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the "Company") (NASDAQ:ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inflammatory diseases, today provided a business updat
4y agoALLKAllakos Announces the Appointment of Dr. Amy Ladd to its Board of DirectorsGlobeNewswireSAN CARLOS, Calif., July 25, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the "Company") (NASDAQ:ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inflammatory diseases, today announced the appointment
4y agoALLKAllakos Provides Business Update and Reports First Quarter 2022 Financial ResultsGlobeNewswireREDWOOD CITY, Calif., May 06, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the "Company") (NASDAQ:ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inflammatory diseases, today provided a business upda
4y agoALLKAllakos Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial ResultsGlobeNewswireREDWOOD CITY, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the "Company") (NASDAQ:ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inflammatory diseases, today provided a business up
4y agoALLKAllakos to Host Investor Day on February 15GlobeNewswire– Management will discuss lirentelimab development and Allakos pipeline – REDWOOD CITY, Calif., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the "Company" or "Allakos") (NASDAQ:ALLK), a biotechnology company developing lirentelimab (AK002) fo
4y agoALLK OPK OSMT SAN+1Thinking about buying stock in Allakos, 22nd Century Group, Osmotica Pharmaceuticals, Banco Santander SA, or Opko Health?PR NewswireNEW YORK, Dec. 23, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ALLK, XXII, OSMT, SAN, and OPK. To
4y agoALLK JAGX OSCR PTPI+1Thinking about buying stock in SeaChange International, Allakos, Petros Pharmaceuticals, Oscar Health, or Jaguar Health?PR NewswireNEW YORK, Dec. 22, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SEAC, ALLK, PTPI, OSCR, and JAGX.
4y agoALLKAllakos Announces Topline Phase 3 Data from the ENIGMA 2 Study and Phase 2/3 Data from the KRYPTOS Study in Patients with Eosinophilic Gastrointestinal DiseasesGlobeNewswireREDWOOD CITY, Calif., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Allakos Inc. (the "Company" or "Allakos") (NASDAQ:ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today reported data
4y agoALLKA Study to Assess Subcutaneous Lirentelimab (AK002) in Atopic Dermatitis - NCT05155085ClinicalTrials.govThe proportion of subjects who achieve an IGA score of 0 or 1 and a reduction of ≥2 points on a 0-4 IGA scale, Compare efficacy of lirentelimab with placebo in subjects with moderate-to-severe AD as estimated by the proportion of subjects who achieve EASI-75, Proportion of subjects with improvement of pruritus numeric rating scale (NRS) ≥4
4y agoALLKAllakos Announces Expansion of Lirentelimab Development into Atopic Dermatitis, Chronic Spontaneous Urticaria and AsthmaGlobeNewswire– Phase 2 Atopic Dermatitis trial of subcutaneous lirentelimab initiated –– Phase 2/3 Chronic Spontaneous Urticaria trial of subcutaneous lirentelimab to begin in mid 2022 –– Phase 2 Asthma trial of subcutaneous lirentelimab to begin in Q4 2022
5y agoALLKAllakos Provides Business Update and Reports Third Quarter 2021 Financial ResultsGlobeNewswireREDWOOD CITY, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Allakos Inc. (the "Company") (NASDAQ:ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today provided a business update
5y agoALLKAllakos Presents Data at ACG 2021 from Prospective Study Showing High Prevalence Rates of Eosinophilic Gastritis and/or Eosinophilic Duodenitis with Systematic EvaluationGlobeNewswire– Study shows 45% (181/405) of patients with moderate-to-severe unexplained gastrointestinal symptoms who underwent upper endoscopy with biopsy met the histologic criteria for eosinophilic gastritis and/or eosinophilic duodenitis (EG/EoD) –– Pre
5y agoALLKAllakos Announces Multiple Presentations Related to Eosinophil and Mast Cell-Driven Diseases at the American College of Gastroenterology 2021 Annual Scientific MeetingGlobeNewswireREDWOOD CITY, Calif., Oct. 24, 2021 (GLOBE NEWSWIRE) -- Allakos Inc. (the "Company") (NASDAQ:ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell related diseases, today announced the acceptance o
5y agoALLKAllakos Provides Business Update and Reports Second Quarter 2021 Financial ResultsGlobeNewswireREDWOOD CITY, Calif., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Allakos Inc. (the "Company") (NASDAQ:ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today provided a business update
5y agoALLKAllakos Completes Patient Enrollment in Phase 3 Eosinophilic Gastritis and/or Eosinophilic Duodenitis and Phase 2/3 Eosinophilic Esophagitis Clinical Trials of Lirentelimab (AK002)GlobeNewswire-- Results from both clinical trials expected in the fourth quarter of 2021 -- -- CMO Dr. Henrik Rasmussen to retire; Dr. Craig Paterson, SVP of Clinical Development and Medical Affairs, promoted to CMO -- REDWOOD CITY, Calif., June 07, 2021 (GLO
5y agoALLKNew Allakos Data Presented at DDW 2021 Suggest that Eosinophilic Gastritis and/or Eosinophilic Duodenitis (EG/EoD) is Highly Underdiagnosed and may be a Common Cause of Moderate-to-Severe Gastrointestinal SymptomsGlobeNewswireREDWOOD CITY, Calif., May 24, 2021 (GLOBE NEWSWIRE) -- Allakos Inc. (the "Company") (NASDAQ:ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, reported data at Digestive Disea
5y agoALLKAllakos Reports First Quarter 2021 Financial Results and Provides Business UpdateGlobeNewswireREDWOOD CITY, Calif., May 10, 2021 (GLOBE NEWSWIRE) -- Allakos Inc. (the "Company") (NASDAQ:ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today reported financial results
5y agoALLKA Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Duodenitis - NCT04856891ClinicalTrials.govProportion of Responders, where a responder is a patient achieving a mean peak duodenal eosinophil count ≤15 cells/3 duodenal hpf., Mean absolute change in TSS as measured by the PRO questionnaire., Percent change in tissue eosinophils, (and 5 more...)